Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens– Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.
To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html
Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status
Key Market Insights
Over 755 CAR-T cell therapies are currently approved / under development
Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.
China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html
Key Questions Answered
§ Who are the leading industry and non-industry players in this market?
§ What are the prevalent R&D trends in CAR-T cell therapies domain?
§ What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
§ What are the challenges faced by stakeholders in this industry?
§ Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
§ What kind of partnership models are commonly adopted by industry stakeholders?
§ What kind of contract manufacturing support is available for CAR-T cell therapies?
§ What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
§ What are the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html mailto:or email [email protected]
You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
2. mRNA Therapeutics and Vaccines Market, 2020-2030
3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
